1. Spasov, A. A., Wikman, G. K., Mandrikov, V. B., Mironova, I. A. & Neumoin, V. V. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine 7, 85–89 (2000).
2. Edwards, D., Heufelder, A. & Zimmermann, A. Therapeutic effects and safety of Rhodiola rosea extract WS® 1375 in subjects with life-stress symptoms–results of an open-label study. Phytother. Res. 26, 1220–1225 (2012).
3. Lekomtseva, Y., Zhukova, I. & Wacker, A. Rhodiola rosea in Subjects with Prolonged or Chronic Fatigue Symptoms: Results of an Open-Label Clinical Trial. Complement Med Res 24, 46–52 (2017).
4. Vigna, L. et al. Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers? Evid. Based. Complement. Alternat. Med. 2019, 7861297 (2019).
5. Chin, E. W. M. & Goh, E. L. K. Modulating neuronal plasticity with choline. Neural Regeneration Res. 14, 1697–1698 (2019).
6. Chin, E. W. M. & Goh, E. L. K. Modulating neuronal plasticity with choline. Neural Regeneration Res. 14, 1697–1698 (2019).
7. Wang, J., Zhang, H.-Y. & Tang, X.-C. Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacol. Sin. 30, 879–888 (2009).
8. Parnetti, L., Mignini, F., Tomassoni, D., Traini, E. & Amenta, F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J. Neurol. Sci. 257, 264–269 (2007).
9. Gibellini, F. & Smith, T. K. The Kennedy pathway–De novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life 62, 414–428 (2010).
10. Babb, S. M., Appelmans, K. E., Renshaw, P. F., Wurtman, R. J. & Cohen, B. M. Differential effect of choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology 127, 88–94 (1996).
11. Fioravanti, M. & Yanagi, M. Cytidinediphosphocholine (choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst. Rev. CD000269 (2005).
12. Calabrese, C. et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J. Altern. Complement. Med. 14, 707–713 (2008).
13. Kumar, N. et al. Efficacy of Standardized Extract of Bacopa monnieri (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial. Evid. Based. Complement. Alternat. Med. 2016, 4103423 (2016).
14. Stough, C. et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology 156, 481–484 (2001).
15. Singh, S. K., Srivastav, S., Castellani, R. J., Plascencia-Villa, G. & Perry, G. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics 16, 666–674 (2019).
16. Yuan, Q., Wang, C.-W., Shi, J. & Lin, Z.-X. Effects of Ginkgo biloba on dementia: An overview of systematic reviews. J. Ethnopharmacol. 195, 1–9 (2017).
17. Mullen, W. et al. The antioxidant and chlorogenic acid profiles of whole coffee fruits are influenced by the extraction procedures. J. Agric. Food Chem. 59, 3754–3762 (2011).
18. Duangjai, A. et al. Comparison of antioxidant, antimicrobial activities and chemical profiles of three coffee (Coffea arabica L.) pulp aqueous extracts. Integr Med Res 5, 324–331 (2016).
19. Reyes-Izquierdo, T. et al. Modulatory effect of coffee fruit extract on plasma levels of brain-derived neurotrophic factor in healthy subjects. Br. J. Nutr. 110, 420–425 (2013).
20. Reyes-Izquierdo, T., Argumedo, R., Shu, C., Nemzer, B. & Pietrzkowski, Z. Stimulatory Effect of Whole Coffee Fruit Concentrate Powder on Plasma Levels of Total and Exosomal Brain-Derived Neurotrophic Factor in Healthy Subjects: An Acute Within-Subject Clinical Study. FNS 04, 984–990 (2013).
21. Calabrese, F. et al. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front. Cell. Neurosci. 8, 430 (2014).
22. Rossi, C. et al. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur. J. Neurosci. 24, 1850–1856 (2006).
23. Cohen-Cory, S., Kidane, A. H., Shirkey, N. J. & Marshak, S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev. Neurobiol. 70, 271–288 (2010).
24. Bekinschtein, P. et al. BDNF is essential to promote persistence of long-term memory storage. Proc. Natl. Acad. Sci. U. S. A. 105, 2711–2716 (2008).
25. Chen, S.-D., Wu, C.-L., Hwang, W.-C. & Yang, D.-I. More Insight into BDNF against Neurodegeneration: Anti-Apoptosis, Anti-Oxidation, and Suppression of Autophagy. Int. J. Mol. Sci. 18, (2017).
26. Dos Santos, T. C., Gomes, T. M., Pinto, B. A. S., Camara, A. L. & Paes, A. M. de A. Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer’s Disease Therapy. Front. Pharmacol. 9, 1192 (2018).
27. Yang, G., Wang, Y., Tian, J. & Liu, J.-P. Huperzine A for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One 8, e74916 (2013).
28. Xing, S.-H., Zhu, C.-X., Zhang, R. & An, L. Huperzine a in the treatment of Alzheimer’s disease and vascular dementia: a meta-analysis. Evid. Based. Complement. Alternat. Med. 2014, 363985 (2014).
29. Zheng, W. et al. Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Shanghai Arch Psychiatry 28, 64–71 (2016).
30. Rosca, M. G., Lemieux, H. & Hoppel, C. L. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv. Drug Deliv. Rev. 61, 1332–1342 (2009).
31. Hagen, T. M. et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc. Natl. Acad. Sci. U. S. A. 95, 9562–9566 (1998).
32. Nicassio, L. et al. Dietary supplementation with acetyl-l-carnitine counteracts age-related alterations of mitochondrial biogenesis, dynamics and antioxidant defenses in brain of old rats. Exp. Gerontol. 98, 99–109 (2017).
33. Smeland, O. B., Meisingset, T. W., Borges, K. & Sonnewald, U. Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice. Neurochem. Int. 61, 100–107 (2012).
34. Kobayashi, S. et al. Acetyl-L-carnitine improves aged brain function. Geriatr. Gerontol. Int. 10 Suppl 1, S99–106 (2010).
35. Aliev, G. et al. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J. Cell. Mol. Med. 13, 320–333 (2009).
36. Parnetti, L., Gaiti, A., Mecocci, P., Cadini, D. & Senin, U. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur. J. Clin. Pharmacol. 42, 89–93 (1992).
37. Dhitavat, S., Ortiz, D., Shea, T. B. & Rivera, E. R. Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochem. Res. 27, 501–505 (2002).
38. Cristofano, A. et al. Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer’s Dementia. PLoS One 11, e0155694 (2016).
39. Malaguarnera, M. et al. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch. Gerontol. Geriatr. 46, 181–190 (2008).
40. Montgomery, S. A., Thal, L. J. & Amrein, R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int. Clin. Psychopharmacol. 18, 61–71 (2003).
41. Veronese, N. et al. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom. Med. 80, 154–159 (2018).
42. Steenge, G. R., Verhoef, P. & Katan, M. B. Betaine supplementation lowers plasma homocysteine in healthy men and women. J. Nutr. 133, 1291–1295 (2003).
43. Olthof, M. R., van Vliet, T., Boelsma, E. & Verhoef, P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J. Nutr. 133, 4135–4138 (2003).
44. Rajaie, S. & Esmaillzadeh, A. Dietary choline and betaine intakes and risk of cardiovascular diseases: review of epidemiological evidence. ARYA Atheroscler. 7, 78–86 (2011).
45. Zhao, G. et al. Betaine in Inflammation: Mechanistic Aspects and Applications. Front. Immunol. 9, 1070 (2018).
46. Eussen, S. J. P. M. et al. The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people. Br. J. Nutr. 98, 960–968 (2007).
47. Knight, L. S., Piibe, Q., Lambie, I., Perkins, C. & Yancey, P. H. Betaine in the Brain: Characterization of Betaine Uptake, its Influence on Other Osmolytes and its Potential Role in Neuroprotection from Osmotic Stress. Neurochem. Res. 42, 3490–3503 (2017).
48. Kim, S. J., Lee, L., Kim, J. H., Lee, T. H. & Shim, I. Antidepressant-like effects of lycii radicis cortex and betaine in the forced swimming test in rats. Biomol. Ther. 21, 79–83 (2013).
49. Di Pierro, F., Orsi, R. & Settembre, R. Role of betaine in improving the antidepressant effect of S-adenosyl-methionine in patients with mild-to-moderate depression. J. Multidiscip. Healthc. 8, 39–45 (2015).
50. Di Pierro, F. & Settembre, R. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression. Int. J. Gen. Med. 8, 73–78 (2015).
51. Hausenblas, H. A., Saha, D., Dubyak, P. J. & Anton, S. D. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J. Integr. Med. 11, 377–383 (2013).
52. Yang, X. et al. Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials. Neuropsychiatr. Dis. Treat. 14, 1297–1305 (2018).
53. Khaksarian, M. et al. The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: a systematic review and meta-analysis.
54. Agha-Hosseini, M. et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG 115, 515–519 (2008).
55. Akhondzadeh, S. et al. Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial. J. Clin. Pharm. Ther. 35, 581–588 (2010).
56. Akhondzadeh, S. et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease. Psychopharmacology 207, 637–643 (2010).
57. Lopresti, A. L. & Drummond, P. D. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum. Psychopharmacol. 29, 517–527 (2014).
58. Bukhari, S. I., Manzoor, M. & Dhar, M. K. A comprehensive review of the pharmacological potential of Crocus sativus and its bioactive apocarotenoids. Biomed. Pharmacother. 98, 733–745 (2018).
59. Cornford, E. M. & Oldendorf, W. H. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim. Biophys. Acta 394, 211–219 (1975).
60. Cansev, M. Uridine and cytidine in the brain: their transport and utilization. Brain Res. Rev. 52, 389–397 (2006).
61. Wurtman, R. J., Cansev, M. & Ulus, I. H. Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J. Nutr. Health Aging 13, 189–197 (2009).
62. Wurtman, R. J., Cansev, M., Sakamoto, T. & Ulus, I. Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr. Rev. 68 Suppl 2, S88–101 (2010).
63. Neary, J. T., Rathbone, M. P., Cattabeni, F., Abbracchio, M. P. & Burnstock, G. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci. 19, 13–18 (1996).
64. Gallai, V., Mazzotta, G., Montesi, S., Sarchielli, P. & Del Gatto, F. Effects of uridine in the treatment of diabetic neuropathy: an electrophysiological study. Acta Neurol. Scand. 86, 3–7 (1992).
65. Kondo, D. G. et al. Open-label uridine for treatment of depressed adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. 21, 171–175 (2011).
66. Gottesmann, C. GABA mechanisms and sleep. Neuroscience 111, 231–239 (2002).
67. Abdou, A. M. et al. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors 26, 201–208 (2006).
68. Möhler, H. Role of GABAA receptors in cognition. Biochem. Soc. Trans. 37, 1328–1333 (2009).
69. Losi, G., Mariotti, L. & Carmignoto, G. GABAergic interneuron to astrocyte signalling: a neglected form of cell communication in the brain. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369, 20130609 (2014).
70. Schmidt-Wilcke, T. et al. GABA-from Inhibition to Cognition: Emerging Concepts. Neuroscientist 24, 501–515 (2018).
71. Sumner, P., Edden, R. A. E., Bompas, A., Evans, C. J. & Singh, K. D. More GABA, less distraction: a neurochemical predictor of motor decision speed. Nat. Neurosci. 13, 825–827 (2010).
72. Steenbergen, L., Sellaro, R., Stock, A.-K., Beste, C. & Colzato, L. S. γ-Aminobutyric acid (GABA) administration improves action selection processes: a randomised controlled trial. Sci. Rep. 5, 12770 (2015).
73. Leonte, A., Colzato, L. S., Steenbergen, L., Hommel, B. & Akyürek, E. G. Supplementation of gamma-aminobutyric acid (GABA) affects temporal, but not spatial visual attention. Brain Cogn. 120, 8–16 (2018).
74. Keynan, O., Mirovsky, Y., Dekel, S., Gilad, V. H. & Gilad, G. M. Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. Pain Med. 11, 356–368 (2010).
75. Shopsin, B. The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsychiatr. 25, 113–118 (2013).
76. Park, C. H. et al. Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11. J. Neurosci. Res. 70, 484–492 (2002).
77. Li, Z. et al. Memory-Enhancing Effects of the Crude Extract of Polygala tenuifolia on Aged Mice. Evid. Based. Complement. Alternat. Med. 2014, 392324 (2014).
78. Xue, W. et al. Polygalasaponin XXXII from Polygala tenuifolia root improves hippocampal-dependent learning and memory. Acta Pharmacol. Sin. 30, 1211–1219 (2009).
79. Park, H.-J. et al. Effects of Polygala tenuifolia root extract on proliferation of neural stem cells in the hippocampal CA1 region. Phytother. Res. 22, 1324–1329 (2008).
80. Fernstrom, J. D. & Fernstrom, M. H. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J. Nutr. 137, 1539S–1547S; discussion 1548S (2007).
81. Goldstein, D. S. Catecholamines 101. Clin. Auton. Res. 20, 331–352 (2010).
82. Lehnert, H., Reinstein, D. K., Strowbridge, B. W. & Wurtman, R. J. Neurochemical and behavioral consequences of acute, uncontrollable stress: effects of dietary tyrosine. Brain Res. 303, 215–223 (1984).
83. Hase, A., Jung, S. E. & aan het Rot, M. Behavioral and cognitive effects of tyrosine intake in healthy human adults. Pharmacol. Biochem. Behav. 133, 1–6 (2015).
84. Jongkees, B. J., Hommel, B., Kühn, S. & Colzato, L. S. Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands–A review. J. Psychiatr. Res. 70, 50–57 (2015).
85. Simpson, T., Kure, C. & Stough, C. Assessing the Efficacy and Mechanisms of Pycnogenol® on Cognitive Aging From In Vitro Animal and Human Studies. Front. Pharmacol. 10, 694 (2019).
86. Pipingas, A. et al. Improved cognitive performance after dietary supplementation with a Pinus radiata bark extract formulation. Phytother. Res. 22, 1168–1174 (2008).
87. Theadom, A. et al. Enzogenol for cognitive functioning in traumatic brain injury: a pilot placebo-controlled RCT. Eur. J. Neurol. 20, 1135–1144 (2013).
88. Belcaro, G., Luzzi, R., Dugall, M., Ippolito, E. & Saggino, A. Pycnogenol® improves cognitive function, attention, mental performance and specific professional skills in healthy professionals aged 35-55. J. Neurosurg. Sci. 58, 239–248 (2014).
89. Belcaro, G. et al. The COFU3 Study. Improvement in cognitive function, attention, mental performance with Pycnogenol® in healthy subjects (55-70) with high oxidative stress. J. Neurosurg. Sci. 59, 437–446 (2015).
90. Hosoi, M. et al. Pycnogenol® supplementation in minimal cognitive dysfunction. J. Neurosurg. Sci. 62, 279–284 (2018).
91. Swaminathan, R. Magnesium metabolism and its disorders. Clin. Biochem. Rev. 24, 47–66 (2003).
92. Clerc, P. et al. Magnesium sulfate protects against the bioenergetic consequences of chronic glutamate receptor stimulation. PLoS One 8, e79982 (2013).
93. Lambuk, L. et al. Neuroprotective Effect of Magnesium Acetyltaurate Against NMDA-Induced Excitotoxicity in Rat Retina. Neurotox. Res. 31, 31–45 (2017).
94. Uysal, N. et al. Timeline (Bioavailability) of Magnesium Compounds in Hours: Which Magnesium Compound Works Best? Biol. Trace Elem. Res. 187, 128–136 (2019).
95. Chiu, H.-Y., Yeh, T.-H., Huang, Y.-C. & Chen, P.-Y. Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials. Pain Physician 19, E97–112 (2016).
96. Boyle, N. B., Lawton, C. & Dye, L. The Effects of Magnesium Supplementation on Subjective Anxiety and Stress-A Systematic Review. Nutrients 9, (2017).
97. Li, B., Lv, J., Wang, W. & Zhang, D. Dietary magnesium and calcium intake and risk of depression in the general population: A meta-analysis. Aust. N. Z. J. Psychiatry 51, 219–229 (2017).
98. Rajizadeh, A., Mozaffari-Khosravi, H., Yassini-Ardakani, M. & Dehghani, A. Effect of magnesium supplementation on depression status in depressed patients with magnesium deficiency: A randomized, double-blind, placebo-controlled trial. Nutrition 35, 56–60 (2017).
99. Tarleton, E. K., Littenberg, B., MacLean, C. D., Kennedy, A. G. & Daley, C. Role of magnesium supplementation in the treatment of depression: A randomized clinical trial. PLoS One 12, e0180067 (2017).
100. Eby, G. A. & Eby, K. L. Rapid recovery from major depression using magnesium treatment. Med. Hypotheses 67, 362–370 (2006).